Related Experiment Video
Updated: May 27, 2025
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy
Stéphanie Kristina Schwarting1,2, Thomas Bieber3,4, Daniel R Davies5
1Department of Medicine I, LMU University Hospital, Ludwig Maximillian University of Munich, Germany (S.K.S., U.G., S.M., S.K.).
Insights
Transthyretin amyloid cardiomyopathy (ATTR-CM) heart failure treatments are uncertain. This review explores current heart failure medication use in ATTR-CM, considering disease specifics and guideline relevance.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Amyloidosis Research
Background:
- Cardiac amyloidosis is an underdiagnosed infiltrative cardiomyopathy causing heart failure.
- Transthyretin amyloid cardiomyopathy (ATTR-CM) has approved therapies, but heart failure medication roles are unclear.
- Current guidelines for heart failure drugs may not apply to ATTR-CM.
Purpose of the Study:
- To explore the use of heart failure medications in ATTR-CM.
- To consider disease stage and patient-specific issues in ATTR-CM treatment.
- To reassess the impact of contemporary heart failure drugs in ATTR-CM.
Main Methods:
- Literature review of current heart failure medications in ATTR-CM.
- Analysis of patient-specific factors like fluid homeostasis and autonomic dysfunction.
- Evaluation of guideline recommendations for heart failure drugs.
Main Results:
- The efficacy of standard heart failure medications in ATTR-CM remains largely unknown.
- ATTR-CM presents unique challenges including autonomic dysfunction and low stroke volumes.
- Existing guidelines based on ejection fraction may need reconsideration for ATTR-CM.
Conclusions:
- Further research is needed to clarify the role of heart failure medications in ATTR-CM.
- Treatment strategies must account for the specific pathophysiology of ATTR-CM.
- Clinical guidelines require re-evaluation for patients with transthyretin amyloid cardiomyopathy.
Abstract:
Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of heart failure medications remains uncertain and challenging in clinical practice. Their effects on clinical outcomes, such as mortality and hospitalization, are unknown for ATTR-CM. This review aims to explore the use of these medications in ATTR-CM, considering the disease's stage and patient-specific issues, such as fluid homeostasis, autonomic dysfunction, conduction disorders, low and fixed stroke volumes, and decreased functional capacity. As our understanding of this condition deepens, it is important to reassess the impact of contemporary heart failure medication in ATTR-CM. Finally, the relevance of guideline recommendations for heart failure drugs based on left ventricular ejection fraction should be reconsidered in the context of ATTR-CM.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure Drugs: Inotropic Agents
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:22Heart Failure Drugs: Diuretics
01:22Heart Failure Drugs: β-Blockers
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...